Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Early USA testing was all done by the CDC and all samples were having to be shipped to one state. And they had a quality problem with one reagent causing early reliability issues. Now more than 20 labs across USA have tests so the idea is USA surgeries can millions of tests which can be processed locally. If the BBC story turns out good and a simple home test can be developed and sold to us all, that will be the truly transformative thing.
Late Friday USA when pence said all that is after close of market here, so any price effect will show up Monday. It's only one market, of course. BBC had science commentators saying an in named firm is developing an instant test that can be made cheaply and used by anyone to test at home, and know in minutes, without any large very expensive equipment. Now I would buy a few of that test for family, even it they sold it at £50 a pop, and whichever firm brings THAT to the market can access a vastly bigger market than official health services providers, whether public or private, based on people's great interest and concern. If anybody can find out which firm is working on that, which sounds different to novacyt's and the other tests I have been reading about, that sounds well worth investing in if it's a listed entity and not a state laboratory. A lot of very well funded state laboratories are working on this, plus unlisted private labs getting vast wedges of cash from various governments around the world which annoyingly significantly undermines the business model of firms like novacyt (unless they can get on that test and access some of this government R&D largesse, which presumably can't be ruled out - there's a positive thought). I know some of you only want to read 100% positive posts - I see that some people can't abide anything else - but you should welcome challenge to your thinking, even if you decide the point made can be discounted. The market has no emotional affiliation to any given share, so we shouldn't.
In a press conference late on Friday, Vice President Mike Pence said that the government has the capacity to provide over 1 million tests. Joined by representatives of the Food and Drug Administration, the Centers for Disease Control and Prevention, and the National Institute for Allergy and Infectious Diseases, he said the CDC will distribute test kits capable of testing over 1.1 million people by the end of THIS weekend, and another 1 million tests will be in quality assurance testing by next week, which Food and Drug Administration Commissioner Dr. Stephen Hahn validated as true. Now, Pence is saying that the capacity to conduct at least 2.1 million tests will be available by next week — and that a consortium of private testing companies will add still more capacity as time goes by. So these tests are coming from numerous providers, but in USA going forward these have to be American, see my post of 5 minutes ago
On Feb. 29, the Food and Drug Administration announced that it was relaxing the restrictions for the use of diagnostic tests for SARS-CoV-2 developed by laboratories in the United States (BUT NOT ELSEWHERE) that meet the certification guidelines for high-complexity testing. The new policy allows these laboratories to begin using in-house developed clinical tests for the virus before obtaining the agency’s approval through an emergency use authorization. The FDA noted that “Rapid detection of COVID-19 cases in the United States requires wide availability of diagnostic testing to control the emergence of this rapidly spreading, severe illness.” Laboratories developing their own tests are expected to apply for emergency use authorization from the FDA within 15 days. For instance the Stanford Clinical Virology Laboratory has deployed an in-house diagnostic test for the virus that causes COVID-19. Rapid identification of infected people could help limit the spread of the virus. Across USA 1 million American covid tests have just been distributed (not Stanford's which is being used locally..The test is being used for patients at Stanford Health Care and Stanford Children’s Health)
I still find last substantive rns annoying, "The GWA Partners have concluded that it will not be possible to tie-back the Lincoln Crestal Well to the Aoka Mizu FPSO in 2020 and therefore the installation vessels to carry out this work under contract with the oilfield service provider have been released. The GWA Partners have agreed to continue to build all the previously ordered equipment. If the GWA Partners are unable to obtain approval to extend the suspension consent, the Lincoln Crestal Well will be plugged and abandoned by the Paul B Loyd Jr rig in March 2020, prior to the planned start of the Lincoln Commitment Well.".
That's nuts. Crystal amber fund down 4% today btw
A new test for Covid19 has been developed by a team led by Linfa Wang, an emerging disease specialist at Duke-NUS. In blood samples from recovered patients, the team identified antibodies targeting the spike protein that proved able to block the virus from killing cells in laboratory tests. In parallel, they created synthetic viral proteins that can detect those antibodies in a blood sample without having to use the live virus.
Serological assays need to be carefully validated to be sure they react reliably, but only to antibodies against the novel virus, says Bart Haagmans of Erasmus Medical Center, whose group is also working on serological tests for Covid19 in collaboration with Utrecht University. Indeed, one concern was that the similarity between the viruses that cause severe acute respiratory syndrome and COVID-19 could lead to cross-reactivity, Wang says. But the newly developed test can distinguish the two viruses with very high accuracy and confidence, he says.
Elsewhere, other developments of serological tests are advancing rapidly. A group at the Wuhan Institute of Virology in China used an in-house test to show that serologic testing can be used to confirm infections, a paper published online on 17 February in Emerging Microbes & Infections shows. The technology has ALREADY been commercialized and sold, team member Peng Zhou wrote in an email. EUROIMMUN, a diagnostics manufacturer, announced on 21 February that it has developed its own test to detect COVID-19 virus antibodies. I wonder which of these will actually capture the market ?
It's me saying I told you so, and I am not "short", wouldn't even know how. Financially I have no interest in the movement of this share now, but as an AIM investor in R&D shares I can learn from its movements vicariously. I felt it was looking dangerously frothy yesterday, and so it was. Yahoo finance took same line yesterday, "History tells us that flash-in-the-pan contenders don’t tend to last. No matter how staggering a share price rise seems, massive new interest in a previously unheard-of stock will deflate eventually.
And then selling out at a reasonable price is a lot harder than buying in.
While I do own a few AIM-listed stocks and shares, like video game developer Frontier Developments and multinational marketing firm The Mission Group, these are highly profitable enterprises with solid, long-term track records and high-margin sales growth. The same can’t be said for Novacyt.". See https://uk.finance.yahoo.com/news/coronavirus-test-maker-novacyt-900-151052826.html
Off topic, in reply to the end of that post : Caroline Flack's suicide was by Caroline flack, and followed a horrific attack on her sleeping boyfriend that could have killed or blinded him. Her previous boyfriend Andrew said before the suicide that his relationship with her was toxic and controlling, and ended his tweet with a link to a domestic violence helpline. Meanwhile does anyone know how long patent cases take to be heard and when the court case is ??
Perhaps an interpretation of the II thread "It is also talking to NHS hospitals and Public Health England, and some tests have already been sold". It doesn't state categorically that the tests already sold, are to NHS. But that's a fair interpretation. Did they just take a few samples of the research use only tests (NOT licensed for regular patient use, and the state health monolith wouldn't break the rules) to see what they are like and how easy they look to use ? Perhaps it is that. This doesn't speak of bulk sales for live use on patients....they could be sued for using an unlicensed test if it missed a case. The claimant could say that that was dangerous practice.
The on site nature of the Chinese screening sounds marvellous if it is accepted for use overseas. Transport of samples for testing in an expensive gene sequencer at a separate location is expensive and controversial, as some couriers say they may refuse to keep doing it or want more money. Novacyt says its samples don't have to be cooled during transport to the remote test facility. But if the Chinese technique doesn't need an expensive £6k machine, and can be done there and then in a few minutes, THAT is the real game changer. I speak as a citizen of the world with an interest in defeat of this nasty. Take care that your novacyt shares don't turn out to be a pile of froth.
Nyct is one of many firms that can do a covid19 test, rampers act like it's the only one. Buying it is a binary bet whether its test is the most suitable one. Nothing but 100% positive, ramptastic sentiment is allowed though. Looks frothy now to me.
Other companies are rushing to meet the demand for coronavirus testing as well. On Jan. 28, Salt Lake City-based Co-Diagnostics Inc. reported that it had successfully completed initial verification of an assay to screen for the presence of 2019-nCoV and would be ready to begin distributing its tests to affected markets soon.
Also last week, Austrian diagnostics company Ares Genetics GmbH announced a collaboration with BGI Group to make molecular tests for the new coronavirus available in Europe. The next-generation sequencing service will use BGI reagents. BGI has developed a real-time fluorescence PCR kit for detecting the strain, which produces results in several hours. The test kit has been approved by China’s National Medical Products Administration, and BGI said it has shipped about 50,000 kits to hospitals and disease control centers in China.
Also in the game is Cincinnati-based Meridian Bioscience Inc. The company recently touted its molecular diagnostic test in detecting 2019-nCoV. “The advantage of the Meridian Lyo-Ready 1-Step RT-qPCR Mix is that the assay can be set up and freeze-dried, so that they are highly stable, just requiring the patient sample to be added and the assay run,” said Liang Zhang, general manager for Meridian in China. “This means that patients can be screened very quickly to help stop the spread of the virus.”
Other companies still are monitoring the situation. In a roundup of comments on the potential impact of the coronavirus, released by Wells Fargo analyst Larry Biegelsen, Becton Dickinson said it is doing what it can to support those on the front lines of the crisis. “While BD does not have an official diagnostic test for the coronavirus, we have seen a number of additional orders in the last few weeks for our BD Max molecular system in China as it is an open system and local officials are looking to develop their own content to run tests.” The uptick is not expected to have a significant impact on business.
Someone managed to sell £18k, see the most recent trade showing on LSE.
Other companies are rushing to meet the demand for coronavirus testing as well. On Jan. 28, Salt Lake City-based Co-Diagnostics Inc. reported that it had successfully completed initial verification of an assay to screen for the presence of 2019-nCoV and would be ready to begin distributing its tests to affected markets soon.
Also last week, Austrian diagnostics company Ares Genetics GmbH announced a collaboration with BGI Group to make molecular tests for the new coronavirus available in Europe. The next-generation sequencing service will use BGI reagents. BGI has developed a real-time fluorescence PCR kit for detecting the strain, which produces results in several hours. The test kit has been approved by China’s National Medical Products Administration, and BGI said it has shipped about 50,000 kits to hospitals and disease control centers in China.
Also in the game is Cincinnati-based Meridian Bioscience Inc. The company recently touted its molecular diagnostic test in detecting 2019-nCoV. “The advantage of the Meridian Lyo-Ready 1-Step RT-qPCR Mix is that the assay can be set up and freeze-dried, so that they are highly stable, just requiring the patient sample to be added and the assay run,” said Liang Zhang, general manager for Meridian in China. “This means that patients can be screened very quickly to help stop the spread of the virus.”
Other companies still are monitoring the situation. In a roundup of comments on the potential impact of the coronavirus, released by Wells Fargo analyst Larry Biegelsen, Becton Dickinson said it is doing what it can to support those on the front lines of the crisis. “While BD does not have an official diagnostic test for the coronavirus, we have seen a number of additional orders in the last few weeks for our BD Max molecular system in China as it is an open system and local officials are looking to develop their own content to run tests.” The uptick is not expected to have a significant impact on business.
https://uk.mobile.reuters.com/article/amp/idUKKBN2051ED states there are 5 other firms also developing better tests for covid19. Which will win ?? Impossible to know. New infection stats are now falling for 3 consecutive days which buys us time. This looks like a binary bet now on covid19 and whose test is best, or quickest, easiest to interpret and whether skill is needed, most reliable, or cheapest ..in UK it's a case of who gets NICE approval, whether temporarily or longer term. I am now out of this stock , it's been excellent whatever now happens.
You don't just sink a deep mine at multiple depths overnight in an advanced country. This will take time to do and first more holes to better map the resource before mapping the mine. The newcrest money tranches aren't enough to fund the mine. I think AIM being what it is some people will decide to get out with a view to getting back in a little cheaper (they hope) when a view on production date probably late 21 or 22 is available, having traded the money elsewhere in the meantime.
The difference between this and some is that the assays are really good so long term excellent. The flighty nature of PIs on AIM could be countered by some other money so any slump may with luck be not too far. Long term it's good, this one is not a Kod or an avesoro/aureus.